The drug maker on Friday announced that its wholly owned subsidiary, Eugia Pharma Specialties, has received a final approval from the US Food & Drug Administration (USFDA) for Amphotericin B Liposome for Injection.
In the 10th edition of IIFL Capital Services’ report “Quirks of the Quarter†series, their analysts explore ten themes ranging from sectoral topics such as growth divergence in Food versus HPC, slowdown in Paints, capex increase in QSR to company-specific issues such as ad spends in Dabur, margin in BBQ, Other expenses in DMart, among others.
The product is expected to be launched by Q4 FY23.
Bajaj Healthcare jumped 3.81% to Rs 408.35 after the pharma company announced successfully competition of first ever pre-approval inspection by US Food and Drug Administration (USFDA) of its Vadodara API facility.
Japanese conglomerate SoftBank Group sold 4.5% stake in One 97 Communications (Paytm) via bulk deal on Thursday, 17 November 2022.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
